Summary Many patients with severe refractory asthma, which is insufficiently controlled by additional high-dose of inhaled corticosteroids, require oral corticosteroids and/or immunosuppressant. Clinicians should seek for suitable medications, for its' chronic use may induce high risk of side effects.
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Summary Many patients with severe refractory asthma, which is insufficiently controlled by additional high-dose of inhaled corticosteroids, require oral corticosteroids and/or immunosuppressant. Clinicians should seek for suitable medications, for its' chronic use may induce high risk of side effects.
The purpose of this study was to evaluate the efficacy and safety of nebulized sodium cromoglycate (3-4 times/day) in adult severe asthmatic patients with poorly controlled asthmatic symptoms, despite treatments with high-dose inhaled corticosteroids.
Adult patients with severe asthma (n ¼ 251) were enrolled in a randomized clinical trial at 30 medical centers in Japan. Isotonic saline was used as placebo. The study was conducted for 10 weeks; with initial 2 weeks of observation followed by 8 weeks of treatments. Efficacy was primarily evaluated based on improvements in morning peak expiratory flow after treatment.
All patients who applied inhalation of nebulized sodium cromoglycate (SCG group) or saline (Controls) were treated with high-dose of inhaled corticosteroids (median of beclomethasone dipropionate equivalent dose: 1600 mg/day s) and second-line control therapy including oral corticosteroids. There was no significant difference in morning peak expiratory flow between SCG group and controls. However, when patients were stratified into atopic and non-atopic groups, morning peak expiratory flow had significantly improved in the atopic SCG group compared to atopic Controls.
Additional inhalation of nebulized sodium cromoglycate with inhaled corticosteroids is effective even in patients with severe atopic asthma. This finding shows that nebulized sodium cromoglycate is expected to be new second-line therapeutic option in severe asthma. & 2005 Elsevier Ltd. All rights reserved. 
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Introduction
Currently, asthma treatment guidelines 1,2 had recommended inhaled corticosteroids as first-line control therapy on asthma, and emphasized the combination of other medications (e.g., longacting inhaled b 2 agonists, leukotriene receptor antagonists (LTRAs), and slow-acting theophylline drugs) as second-line control therapy, with higher dose of inhaled corticosteroids in patients with more severe asthma. However, many patients with severe refractory asthma 3 are not fully controlled despite treatments with high-dose of inhaled corticosteroids and other medications. Moreover, increasing dose of inhaled corticosteroids or initiation of oral corticosteroids and/or immunosuppressant is restricted in patients with anti-inflammatory treatments. Since treatments with oral corticosteroids and/or immunosuppressant present risks of side effects, development of therapeutic options not causing dependence on oral corticosteroids and/or immunosuppressant should essentially be considered.
Sodium cromoglycate (SCG) is an anti-inflammatory agent that acts via different mechanisms against corticosteroids. Several studies [4] [5] [6] [7] have evaluated the effects of SCG in the long-term management against mild-to-moderate asthma. Nebulized SCG improves airway obstruction caused by excessive production of sputum, relieves peripheral airway inflammation, and synergism is seen with inhaled corticosteroids or b 2 agonists. This pharmacotherapy is thus considered to be effective against severe asthma.
8 However, few studies have reported the characteristics of patient who shows synergism between nebulized SCG and inhaled corticosteroids.
In this study, the efficacy and safety of nebulized SCG was evaluated in patients with severe asthma, which was inadequately controlled even with highdose of inhaled corticosteroids plus other medications, by comparing isotonic saline as a control. Stratified analysis was also performed to clarify the effects of nebulized SCG.
Methods
Study design
In this study, randomized study was performed by using isotonic saline as a control therapy, at 30 medical centers in Japan. The duration of this study was 10 weeks; 2 weeks of observation to evaluate patients before therapy, followed by 8 weeks of treatment to evaluate the efficacy of nebulized SCG. Nebulized SCG (20 mg of SCG per ampule (2 mL)) was used as a trial drug (SCG group), and nebulized saline (18 mg of sodium chloride per ampule (2 mL)) was used as a control drug (Controls). Both drugs were inhaled 3-4 times/day using electronic nebulizer (Pari Boy 038 s LL Nebulizer; Pari innovative manufacturers, 13800 Hull Street Rd, Midlothian, VA). The biostatistics advisor had randomly assigned treatments on a key code table blindly, and disclosed them after the database was locked.
Study objectives were explained to the patients thoroughly and written informed consent was obtained prior to the study. All study protocols were approved by the institutional review board and the director of each participating medical institution.
Patients
Patients at the age of 20 and older, diagnosed as severe persistent asthma, were enrolled in this study;
Step 4 (Table 1) according to the Classification for Asthma Severity in the Asthma Prevention and Management Guidelines 2000 1 in Japan. All patients had been using one of the following inhaled corticosteroid regimens prior to the study: 4800 mg/day of inhaled beclomethasone dipropionate (BDP-CFC), 4400 mg/day of inhaled fluticasone propionate (FP-DPI), or 4400 mg/day of inhaled budesonide (BUD-DPI). Patients who were using either BDP-CFC 800 mg/day, FP-DPI 400 mg/ day, or BUD-DPI 400 mg/day in combination with oral corticosteroids were also eligible when total dose of steroid exceeded the BDP equivalent dose mentioned above. Additional eligibility criteria were as follows: mean morning peak expiratory flow (PEF) during the observation period o80% of normal predicted value, 1 or diurnal variation in PEF during the observation period 420% were evaluated at least 2 days/each week; asthmatic symptoms (wheezing, dyspnea, or slight asthmatic attack) were reported at least 2 times/week. Moreover, patients who present specific IgE antibodies against environmental allergens (high in serum total IgE levels, allergen-specific IgE positive, and/or allergy skin test positive) were classified as atopic (allergic) asthma. Patients without specific IgE antibodies were classified as non-atopic (non-allergic) asthma.
Patients were excluded from the study if: (1) allergen immunotherapy or other non-specific immunotherapy was initiated p6 months before the observation period, (2) initiation of anti-allergic drugs or LTRAs, switching to another drugs, or use of depo-steroid p3 months before the observation period was enforced, (3) initiation of allergen immunotherapy, other non-specific immunotherapy, anti-allergic drugs, or LTRAs, switching to another drugs, use of depo-steroid during the observation period was enforced, or (4) administration of oral steroid 410 mg/day (predonisolone), changes in dosage of oral steroids, administration of steroid infusion or injection, initiation of long-acting b 2 agonist (inhaled, oral, or topical), oral slow-acting theophylline, inhaled b 2 agonist by nebulizer, or administration of X3 infusions or injections of bronchodilator (e.g., aminophylline) per week were applied.
Evaluation
Outpatients were scheduled to visit medical centers at the start of the observation period for 2 weeks, and at 0, 2, 4, 6 and 8 weeks of treatment period. Patients were instructed to keep records of asthmatic symptoms, PEF values, and treatments each day during the week. PEF was measured twice daily, morning (within 30 min of waking) and evening, with peak flow meter (Mini-Wright s ; Clement Clark International, Harlow, UK). PEF were measured 3 times each in standing position, before the administration of asthmatic medications, and the highest value was recorded. Mean PEF morning and PEF evening were calculated each week. Asthmatic symptoms were scored based on the standard evaluation criteria. 9 They are as follows: asthmatic attack and wheezing on a scale of 0-9 (0 point: no symptoms, 1 point: dyspnea or wheezing, 3 points: slight attack, 6 points: moderate attack, 9 points: severe attack), cough on a scale of 0.5-1 (0.5 point: infrequent cough, 1 point: frequent cough). Treatment status was scored in each concomitant drugs based on the standard evaluation criteria. 9 Pulmonary function was evaluated by spirometer at the start of the treatment, 4 weeks after the initiation of the treatment, and at the end of the treatment. This As asthmatic patients often present prominent morning dip in PEF, 11 PEF morning was used as primary evaluation tool in this study.
Type, severity, time of onset, specific treatment, follow-up, and time of resolution were documented for all adverse events occurred during the study. Patients were monitored closely as possible until the resolution or improvement of symptoms was observed. These adverse events, which a relationship with the treatment of this study could not be denied, were considered as adverse drug reactions.
Any patients who required emergency treatment such as additional oral, injectable, or infused steroids to treat exacerbation of asthmatic symptoms were judged by the investigator, and immediately withdrawn from the study. 
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Statistical methods
The percentage change from baseline at each time point in PEF morning and PEF evening was analyzed by using 2-sample Wilcoxon test between treatment groups. The change from baseline at each time point in PEF morning and PEF evening was also analyzed by the same method. In addition, incidence of responder patients in a contingency table was analyzed by Fisher's exact probability test between treatment groups. Patients were defined as ''responders'' for those who has improved more than or equal to 20 L/min from baseline at the end of treatment in PEF morning , and as ''non-responders'' for those less than 20 L/min, to explore the clinical significance. The above-mentioned specified that the primary endpoint was the percentage change from baseline at the end of the treatment in PEF morning . For the change from baseline at each time point in pulmonary functions (FVC, FEV 1.0 , %FEV 1.0 ), asthmatic symptom score and medication score was analyzed in the same way as in PEF. The change from baseline at the end point in QOL was analyzed by 2-sample t-test between treatment groups. The incidence of treatment discontinuation due to symptom aggravation was analyzed by using Fisher's exact probability test between treatment groups. The incidence of adverse events, treatment discontinuation due to adverse events, and adverse drug reactions were analyzed by the same method. Demographics and baseline characteristics were analyzed by using Fisher's exact probability test for categorical variables and 2-sample Wilcoxon test for continuous variables. All efficacy were analyzed in the Full Analysis Set (FAS), and safety analyses were done on all patients with treatment and safety data, utilizing SAS Release 8.02. All statistical tests were conducted at a 2-sided 0.05 significance level.
Results
Background of the patients
Among 251 patients (SCG group, n ¼ 128; Controls, n ¼ 123) enrolled in the study, 23 patients (SCG group, n ¼ 14; Controls, n ¼ 9) were excluded from efficacy analysis; this included 21 patients (SCG group, n ¼ 13; Controls, n ¼ 8) with protocol violations and 2 patients (SCG group, n ¼ 1; Controls, n ¼ 1) with no treatment. Thus, 228 patients (SCG group, n ¼ 114; Controls, n ¼ 114) were analyzed for efficacy. Five patients (SCG group, n ¼ 4; Controls, n ¼ 1) were excluded from safety analysis; this included 3 patients (SCG group, n ¼ 3) with no safety data and 2 patients (SCG group, n ¼ 1; Controls, n ¼ 1) with no treatment. Thus, 246 patients (SCG group, n ¼ 124; Controls, n ¼ 122) were analyzed for safety. In analysis of clinical characteristics, asthmatic symptom score was significantly higher in Controls than in the SCG group. However, no differences were identified between the 2 groups regarding sex, age, height, disease type, duration of asthma, atopic complications, respiratory complications and/or chronic sinusitis, treatment score, PEF morning , incidence of normal predicted PEF morning , pulmonary function, or QOL score ( Table 2) .
Median dosage of inhaled corticosteroids used during the observation period was BDP-CFC equivalent dose of 1600 mg/day in both SCG group and Controls. In addition to inhaled corticosteroids, other asthmatic medications were administered in all patients: LTRAs, n ¼ 118 (51.8%; SCG group, n ¼ 56; Controls, n ¼ 62); oral slow-acting theophylline, n ¼ 202 (91.2%; SCG group, n ¼ 105; Controls, n ¼ 97); long-acting b 2 agonists, n ¼ 161 (70.6%; SCG group, n ¼ 85; Controls, n ¼ 76); and short-acting inhaled b 2 agonists, n ¼ 168 (73.7%; SCG group, n ¼ 82; Control, n ¼ 86). In addition, oral corticosteroids, with a median dosage of 5 mg/ day (prednisolone equivalent dose), were used in 97 patients (42.5%; SCG group, n ¼ 49; Controls, n ¼ 48) in both SCG group and Controls (Table 3) .
Efficacy
Median percentage change (change) in PEF morning , between observation period and end of treatment, was 3.50%( 8.25 L/min) in the SCG group and 1.67%(6.00 L/min) in Controls, with no significant difference was identified between groups (P ¼ 0:655) (Table 4a , Fig. 1 ). Median percentage change (change) in PEF evening , between observation period and end of treatment was 1.16% (3.25 L/ min) in the SCG group and 1.56% (5.50 L/min) in Controls, with no significant difference was identified between groups (P ¼ 0:609).
Stratified analysis of changes in PEF morning among atopic subgroup was significantly higher in the SCG group compared to Controls at 2 weeks, 4 weeks and end of treatment (Fig. 2, Table 4b ). Stratified analysis of changes in PEF morning among non-atopic subgroup showed no significant difference between the SCG group and Controls (Fig. 3, Table 4b ).
The incidence of responders for PEF morning revealed response rate of 34.8% (n ¼ 39 vs. n ¼ 112) in the SCG group and 24.8% (n ¼ 28 vs. n ¼ 113) in Controls, with no significant difference (P ¼ 0:110).
Distribution of responders was examined in each subgroup. Stratified analysis on disease-type subgroups revealed significant improvement among patients with atopic asthma, with a response rate of 42.6% (n ¼ 29 vs. n ¼ 68) in the SCG group and 22.7% (n ¼ 15 vs. n ¼ 66) in Controls. Incidence of responders was significantly higher in the SCG group (P ¼ 0:017). However, among patients with nonatopic asthma, response rate was 22.7% (n ¼ 10 vs.
n ¼ 44) in the SCG group and 27.7% (n ¼ 13 vs. n ¼ 47) in Controls, with no significant difference. Stratified analysis on respiratory complications and/or chronic sinusitis was performed. Patients without complication showed significant improvement, with a response rate of 37.5% (n ¼ 36 vs. n ¼ 96) in the SCG group and 22.2% (n ¼ 22 vs. n ¼ 99) in Controls. On the other hand, patients with complications showed no significant Table 5) . Analysis of changes in FVC, FEV 1.0 , and %FEV 1.0 , from observation period to the end of treatment, showed no significant difference between groups (Table 6 ). Changes in total ''yes'' responses on the QOL questionnaire from pre-treatment to end of treatment showed À1.773.93 in the SCG group and À1.473.38 in Controls. Scores were not significantly different between groups (P ¼ 0:539).
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No significant difference in analysis of changes in asthmatic symptom scores were shown at any other point of time (P ¼ 0:951). No significant difference in treatment scores were noted between groups (P ¼ 0:402).
Treatment was discontinued during the study for the patients whose symptoms had exacerbated: 13 patients (discontinuation rate of 11.4%) in the SCG group and 11 patients (discontinuation rate of 9.6%) in Controls. No significant difference was identified between groups (P ¼ 0:830).
Safety
Adverse events occurred in 73 patients (58.9%) in the SCG group and 67 patients (54.9%) in Controls. Frequency of adverse events did not differ significantly between groups (P ¼ 0:607). Treatment was discontinued as a result of adverse events in 9 patients (7.3%) in the SCG group and 7 patients (5.7%) in Controls. Incidence regarding discontinuation of treatment due to adverse events showed no significant difference between groups (P ¼ 0:797).
Adverse reactions had occurred in 11 patients (8.9%) in the SCG group and 10 patients (8.2%) in Controls (Table 7) , and no significant difference was identified (P ¼ 1:000). Adverse reactions which required discontinuation of the treatment had occurred in 1 patient (0.8%) in the SCG group and 2 patients (1.6%) in Controls, and no significant difference was seen (P ¼ 0:620).
Discussion
Current asthma treatment guidelines in Europe, the United States, and Japan have recommended inhaled corticosteroids as the first choice for longterm management of asthma. Dose of inhaled corticosteroids and/or addition of other medications (e.g., long-acting inhaled b 2 agonists, LTRAs, oral slow-acting theophylline, antiallergic agents or oral corticosteroids) as a second choice should be considered according to the severity of asthma. If asthma is insufficiently controlled by medium-to 
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End of treatment includes the last recorded value during treatment using trial drug, regardless of withdrawal or completion of the study.
high-dose of inhaled corticosteroids, the combination with other asthmatic medications is recommended, expecting additive and synergistic effects. [12] [13] [14] However, some patients 15,16 treated with high-dose of inhaled corticosteroids, inadequately controlled by additions of long-acting inhaled b 2 agonist or oral corticosteroids, received no significant benefit from further additions of LTRAs. This is attributed to significant airway remodeling and intractable peripheral airway inflammation, as a consequence of reduced response against treatment.
Severe refractory asthma is caused by repetition of airway inflammation with involvement of mast cells, eosinophils, T-cells, and other inflammatory cells induced by various factors. These recurrent inflammation causing structural changes (airway remodeling) may lead to irreversible airway obstruction and airway hypersensitivity. Other complications such as chronic bronchitis, chronic emphysema, and chronic sinusitis may promote refractoriness. Patients with such severe asthma are occasionally taken to emergencies and hospitalized for intravenous therapy. These patients may present insomnia due to aggravated cough, sputum, and anxiety against nocturnal attacks, and treatment with inhaled and oral corticosteroids is often insufficient. In these cases, QOL is neglected not only for patients, but also for their family members. Nevertheless, adequate treatments against severe refractory asthma is not established, and further investigations supported by new clinical evidences are warranted.
SCG is an anti-inflammatory agent that influences a variety of mechanisms against corticosteroids. SCG participates in various inhibitory effects among the process, such as airway inflammation, release of chemical mediators from mast cells, 17 IgE production, 18 T-cell and eosinophil accumulation, 19 eosinophil activation, 20, 21 allergic inflammation, 22 ,23 inflammatory cytokine production, 22 activation of afferent sensory nerves (C-fibers), 24 and induction of cysteinyl leukotoriene synthesis. 25 Combination therapy using SCG may be effective in controlling severe refractory asthmatic symptoms. One report mentioned that adding of nebulized SCG (alone or with b 2 agonist inhaled by nebulizer) in patients with severe asthma had improved pulmonary functions and decreased requirement of oral corticosteroids. 8 Combination of nebulized SCG can reduce the frequency of asthma attacks, minimize the need for emergency care, and hospitalization for intravenous therapy. Thus, successful control can also be achieved in the outpatient, which is one of the primary goals of asthmatic treatment. Many cases were also experienced by the author, in which nebulized SCG had improved asthmatic symptoms in patients with severe asthma.
In this study, evaluation was done to see the efficacy and safety when combining nebulized SCG and inhaled corticosteroids in adults with poorly controlled severe asthma despite treatment with high-dose of inhaled corticosteroids and other medications. Median dosage of inhaled corticosteroids in both SCG group and Controls was 1600 mg/ day (BDP-CFC equivalent dose). Although patients were all taking other medications (oral corticosteroids, 42.5%; long-acting inhaled b 2 agonists, 70.6%; LTRAs, 51.8%; oral slow-acting theophylline, 91.2%), mean PEF morning (median) during the observation period was 60.2% of predicted in the SCG group and 54.5% of predicted in Controls. PEF morning was not significantly different between SCG group and controls. However, when patients were stratified into atopic and non-atopic groups, PEF morning in the atopic SCG group had significantly improved compared to atopic controls. The change in PEF morning , between observation period and end of treatment, were 13.50 L/min in SCG group and 2.25 L/min in controls ''Responders'' in each group were also evaluated for further clinically significant parameter. In PEF morning , X20 L/min is considered to show distinct improvement in daily medical examinations. 26 Response rate was 34.8% in the SCG group and 24.8% in Controls, with 10% of difference. Stratified analysis showed a 20% of difference in response rate in the subgroup of patients with atopic asthma: 42.6% in the SCG group and 22.7% in Controls (P ¼ 0:017). This suggests that addition of nebulized SCG is particularly effective in patients with severe atopic asthma. Approximately 90-95% of asthmatic children are atopic. In a randomized crossover study, b 2 agonist+saline (administered as a nebulized solution) and b 2 agonist+SCG were compared, in children with moderate-to-severe asthma. 27 This reported significant improvements in the b 2 agonist+SCG group. Given the differences between adult and childhood asthma, our results in the atopic subgroup support their results.
Evaluation of the effects on drugs in severe asthmatic patients is difficult, and this study failed to show significant differences between SCG and saline. However, stratified analysis showed significant improvement on SCG in the subgroup of atopic asthma. To provide effective treatment for each individual patient, consideration of which patients are inclined to respond to nebulized SCG would be necessary. Atopic asthma responds to inhaled SCG, and is IgE dependent. Allergic airway inflam-mation proceeds following mechanism. Specific IgE antibodies produced by B cells bind with mast cells and eosinophils. Activation of these cells by allergens causes the release of mediators which trigger asthmatic reactions. In addition, some inflammatory mediators stimulate C-fiber term- tion, IL-4 and IL-13 act on B cells to stimulate IgE antibody production. [28] [29] [30] [31] SCG inhibits these various reactions, as mentioned above. In atopic asthma, clinically the number of Th2-type T cells is increased in alveolar lavage fluid and blood. T-cell activation occurs only with eosinophil infiltration. SCG inhibits expression of VCAM-1 and ICAM-1 associated with eosinophil and T-cell infiltration. This inhibitory effect may be antigen-and Th2-specific, 22, 23 which accounts for more prominent effect of SCG in atopic asthma. However, nonatopic asthma lacks antigen specificity, and the role of allergy-induced inflammation is relatively small. Therefore, SCG may be less effective in non-atopic asthma. Stratified analysis for factors other than disease type, including respiratory complications due to chronic obstructive pulmonary disease and/ or chronic sinusitis, may complicate evaluations on the effects of SCG. In chronic obstructive pulmonary disease, eosinophilic inflammation plays a minor role, whereas neutrophilic inflammation plays a major role, which makes nebulized SCG fail to exert significant effects. Excluding these complications, stratified analysis showed a response rate of 37.5% in the SCG group and 22.2% in Controls (P ¼ 0:028). The number of responders was significantly higher on inhaled SCG with nebulizer. Thus, SCG may be more effective on severe refractory asthma without respiratory complications or chronic sinusitis. Nebulized placebo solution (purified water without active ingredients of nebulized SCG solution) was initially considered for Controls, but worsening of respiratory function was concerned when this purified water was nebulized by asthmatic patients. 32, 33 Therefore saline was selected to minimize the risks of inducing asthmatic attacks. Isotonic saline reportedly had improved pulmonary function in some cases. Even in this study, Controls as a whole displayed improvements in PEF morning compared to observation period.
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In conclusion, addition of nebulized SCG to the treatment regime of adults with severe asthma is considered to be effective. For the patients in the subgroup of atopic asthma, nebulized SCG have produced substantial improvements on PEF morning compared to nebulized saline. This finding is consistent with the pharmacological profile of SCG. Addition of nebulized SCG as second-line control therapy should be considered in patients with severe refractory atopic asthma who are taking inhaled corticosteroids. 
